Cellect Signs Agreement With The Hadassah Technological Transfer Company - Hadasit

TEL AVIV, Israel, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Cellect biotechnology Ltd. (NASDAQ:APOP) (TASE:APOP) (hereinafter the "Company") announces it has signed an agreement with Hadasit, the Technology Transfer Company of Hadassah Medical Organization (HMO) in Jerusalem.

According to the agreement, Hadassah's Prof. Amnon Peled, one of the world's most renowned investigators of stem cells and natural killer cells, will be conducting a series of trials using Cellect's ApoGraft method to test engraftment potential and its effect on lowering GvHD (transplant rejection disease) in mice models. In addition, Prof. Peled will investigate the ApoGraft potential on inducing Graft versus Tumor which may provide significant improvements in cancer treatments.

Shai Yarkoni, Cellect's Co-Founder & CEO, stated: "We are constantly advancing in providing vital medical and research data on the effectiveness of Cellect's technology as the best solution for stem cells-based treatments. We are honored to be working with Prof. Peled and Hadassah for further evidence of what our technology can contribute to the stem cells therapies arena."  

Prof. Amnon Peled stated: "We look forward to collaborating on this project and its results."

Stem cells are extremely rare and difficult to identify and separate from any mass of mature cells. Stem cell transplants contain a high ratio of mature cells, which often causes severe rejection symptoms, morbidity and even death.

One of the key barriers to any future stem cells-based therapies is the lack of ability to separate stem cells effectively to achieve the critical mass of stem cell quantity and quality necessary for regenerative treatments with minimal rejection risks and at a reasonable cost that will make such treatments available for everyone.

Current therapies using stem cells, such as Bone Marrow transplants, suffer from very high levels of risks (e.g. GvHD), low ratios of success and extremely high costs involving complex and mostly ineffective processes trying to reach a critical mass of stem cells material for treatments.  

If you liked this article you might like

Lannett Scores FDA OK for Nexium Generic-Biotech Movers